AstraZeneca to Discontinue Life-Saving Drug Zoladex in Australia
Life-saving breast cancer and endometriosis drug to be discontinued
Image: Abc
AstraZeneca plans to withdraw the breast cancer and endometriosis medication Zoladex from the Australian market by November, citing commercial reasons. Patients have expressed distress over the decision, with AstraZeneca offering a six-month free access program for those lacking alternatives. The drug's removal raises concerns about unmet clinical needs.
- 01Zoladex 3.6mg, used for breast cancer and endometriosis, will be removed from the Pharmaceutical Benefits Scheme (PBS) in November.
- 02Approximately 8,600 patients received the medication in the first quarter of the year.
- 03AstraZeneca's decision is a global move to streamline dosage options, not related to safety or efficacy.
- 04Health authorities are exploring alternative treatment options and the potential expansion of the PBS listing for the 10.8mg dose for breast cancer.
- 05Patients will have free access to Zoladex for six months if they have no alternative treatments.
Advertisement
In-Article Ad
AstraZeneca has announced the withdrawal of Zoladex 3.6mg, a vital drug for breast cancer and endometriosis, from the Australian market by November 2026. This decision has drawn criticism from patients and advocacy groups, who describe it as 'cruel' and 'soul-destroying.' The drug, which helps slow breast cancer growth and manage endometriosis by inhibiting estrogen production, will no longer be available on the Pharmaceutical Benefits Scheme (PBS). AstraZeneca stated that the removal is part of a global strategy to reduce dosage options, not due to safety concerns. Approximately 8,600 patients dispensed the drug in early 2026, leading to fears of unmet clinical needs. In response, AstraZeneca will provide free access to Zoladex for six months for patients without alternative treatments. Health officials are working to find other options and are hopeful about expanding the PBS listing for a higher dose of Zoladex for breast cancer patients. The PBS system, which subsidizes medication costs, has faced criticism from pharmaceutical companies regarding pricing negotiations.
Advertisement
In-Article Ad
The withdrawal of Zoladex will leave many breast cancer and endometriosis patients without a crucial treatment option, potentially affecting their health outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about AstraZeneca's decision to withdraw Zoladex?
Connecting to poll...
More about AstraZeneca
Laura Colón de AstraZeneca advierte sobre la competitividad de Europa frente a Estados Unidos
Crónica Global • Jun 3, 2026
La FDA extiende la revisión de camizestrant de AstraZeneca para el cáncer de mama
Investing • May 27, 2026
Empresas em Portugal Implementam Políticas de Incentivo à Natalidade
Jornal Economico • May 22, 2026
Read the original article
Visit the source for the complete story.